I sold down some more. OCC is an interesting beast but I've been...

I sold down some more. OCC is an interesting beast but I've been waiting for a while for a re-rate. Given it's been above 60c in what I would call a weaker position, it's a tad bemusing to see it languishing here - no doubt a reflection of emerging biotech sentiment over the last couple of years. The sales have been a bit disappointing but perhaps I had higher expectations? No real negatives on management and financial position just seems unloved until more sales and products arrive. Still have some and would rather buy back later even at a higher price when the action starts?? GLTA